使用 MitraClip™ 进行二尖瓣经导管边缘至边缘修补术的结果 - 印度单中心经验。

IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Indian heart journal Pub Date : 2024-09-01 DOI:10.1016/j.ihj.2024.09.002

Sai Satish , Vijayakumar Subban , Yerramareddy Vijayachandra , Abraham Oomman , Ganapathy Arumugam , Hemalatha Senthil , Hema Kethavath , Kamala Devi Pulindram , Saibal Kar , Susheel Kodali , Krishnaswamy Chandrasekaran

{"title":"使用 MitraClip™ 进行二尖瓣经导管边缘至边缘修补术的结果 - 印度单中心经验。","authors":"Sai Satish , Vijayakumar Subban , Yerramareddy Vijayachandra , Abraham Oomman , Ganapathy Arumugam , Hemalatha Senthil , Hema Kethavath , Kamala Devi Pulindram , Saibal Kar , Susheel Kodali , Krishnaswamy Chandrasekaran","doi":"10.1016/j.ihj.2024.09.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the outcomes of transcatheter edge-to-edge repair (TEER) with MitraClip™ (Abbott Vascular) in symptomatic high surgical risk Indian patients with significant mitral regurgitation (MR).</div></div><div><h3>Methods</h3><div>Patients with moderately severe or severe primary or secondary MR and deemed high surgical risk were treated with MitraClip™. The data were collected retrospectively from medical records. The primary outcome was technical success, and secondary outcomes were ≤2+ MR reduction and improvement in functional capacity at 30 days.</div></div><div><h3>Results</h3><div>Between November 2018 and August 2023, 64 patients were treated with MitraClip<sup>TM</sup>. The mean age was 70.0 ± 12.1 years and 64 % were males. The mean EuroScore II and STS score predicted mortality for mitral valve repair were 5.8 ± 4.5 % and 4.0 ± 3.8 % respectively. MR etiology was primary in 56.3 %, secondary in 40.6 % and mixed in 3.1 %. The device was implanted successfully in all but one patient with technical success rate of 98.4 %. The average number of clips per patient was 1.5 ± 0.6 and 42.2 % patients received more than one clip. The mean mitral valve gradient was 3.5 ± 1.6 mmHg. The MR severity of ≤2+ was achieved in 91.8 % of the subjects and similar proportion were in New York Heart Association Functional Class I or II at 30 days.</div></div><div><h3>Conclusion</h3><div>In high-risk Indian patients with symptomatic significant MR, TEER with MitraClip™ was achieved with a high technical success rate. It was associated with significant reduction in MR severity and improvement in functional capacity in >90 % of the subjects.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 5","pages":"Pages 315-320"},"PeriodicalIF":1.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of mitral transcatheter edge to edge repair with MitraClip™ – An Indian single center experience\",\"authors\":\"Sai Satish , Vijayakumar Subban , Yerramareddy Vijayachandra , Abraham Oomman , Ganapathy Arumugam , Hemalatha Senthil , Hema Kethavath , Kamala Devi Pulindram , Saibal Kar , Susheel Kodali , Krishnaswamy Chandrasekaran\",\"doi\":\"10.1016/j.ihj.2024.09.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To evaluate the outcomes of transcatheter edge-to-edge repair (TEER) with MitraClip™ (Abbott Vascular) in symptomatic high surgical risk Indian patients with significant mitral regurgitation (MR).</div></div><div><h3>Methods</h3><div>Patients with moderately severe or severe primary or secondary MR and deemed high surgical risk were treated with MitraClip™. The data were collected retrospectively from medical records. The primary outcome was technical success, and secondary outcomes were ≤2+ MR reduction and improvement in functional capacity at 30 days.</div></div><div><h3>Results</h3><div>Between November 2018 and August 2023, 64 patients were treated with MitraClip<sup>TM</sup>. The mean age was 70.0 ± 12.1 years and 64 % were males. The mean EuroScore II and STS score predicted mortality for mitral valve repair were 5.8 ± 4.5 % and 4.0 ± 3.8 % respectively. MR etiology was primary in 56.3 %, secondary in 40.6 % and mixed in 3.1 %. The device was implanted successfully in all but one patient with technical success rate of 98.4 %. The average number of clips per patient was 1.5 ± 0.6 and 42.2 % patients received more than one clip. The mean mitral valve gradient was 3.5 ± 1.6 mmHg. The MR severity of ≤2+ was achieved in 91.8 % of the subjects and similar proportion were in New York Heart Association Functional Class I or II at 30 days.</div></div><div><h3>Conclusion</h3><div>In high-risk Indian patients with symptomatic significant MR, TEER with MitraClip™ was achieved with a high technical success rate. It was associated with significant reduction in MR severity and improvement in functional capacity in >90 % of the subjects.</div></div>\",\"PeriodicalId\":13384,\"journal\":{\"name\":\"Indian heart journal\",\"volume\":\"76 5\",\"pages\":\"Pages 315-320\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian heart journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0019483224001822\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian heart journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0019483224001822","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

目的评估MitraClip™（雅培血管公司）经导管边缘到边缘修补术（TEER）对有症状的高手术风险印度二尖瓣返流（MR）患者的治疗效果：中重度或重度原发性或继发性二尖瓣反流并被视为手术风险高的患者接受 MitraClip™ 治疗。数据通过病历回顾性收集。主要结果是技术成功率，次要结果是≤2+MR缩小和30天后功能改善：2018年11月至2023年8月期间，64名患者接受了MitraClip治疗。平均年龄为（70.0±12.1）岁，64%为男性。欧洲评分 II 和 STS 评分预测的二尖瓣修复死亡率平均值分别为 5.8 ± 4.5% 和 4.0 ± 3.8%。MR病因56.3%为原发性，40.6%为继发性，3.1%为混合性。除一名患者外，所有患者都成功植入了该装置，技术成功率为 98.4%。每位患者平均使用 1.5 ± 0.6 个夹子，42.2% 的患者使用了一个以上的夹子。二尖瓣平均梯度为 3.5 ± 1.6 mmHg。91.8%的受试者的MR严重程度达到≤2+，类似比例的受试者在30天后达到纽约心脏协会功能分级I级或II级：结论：对于有明显 MR 症状的印度高危患者，MitraClip™ TEER 的技术成功率很高。90%以上的受试者的 MR 严重程度明显减轻，功能得到改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcomes of mitral transcatheter edge to edge repair with MitraClip™ – An Indian single center experience

Objective

To evaluate the outcomes of transcatheter edge-to-edge repair (TEER) with MitraClip™ (Abbott Vascular) in symptomatic high surgical risk Indian patients with significant mitral regurgitation (MR).

Methods

Patients with moderately severe or severe primary or secondary MR and deemed high surgical risk were treated with MitraClip™. The data were collected retrospectively from medical records. The primary outcome was technical success, and secondary outcomes were ≤2+ MR reduction and improvement in functional capacity at 30 days.

Results

Between November 2018 and August 2023, 64 patients were treated with MitraClip^TM. The mean age was 70.0 ± 12.1 years and 64 % were males. The mean EuroScore II and STS score predicted mortality for mitral valve repair were 5.8 ± 4.5 % and 4.0 ± 3.8 % respectively. MR etiology was primary in 56.3 %, secondary in 40.6 % and mixed in 3.1 %. The device was implanted successfully in all but one patient with technical success rate of 98.4 %. The average number of clips per patient was 1.5 ± 0.6 and 42.2 % patients received more than one clip. The mean mitral valve gradient was 3.5 ± 1.6 mmHg. The MR severity of ≤2+ was achieved in 91.8 % of the subjects and similar proportion were in New York Heart Association Functional Class I or II at 30 days.

Conclusion

In high-risk Indian patients with symptomatic significant MR, TEER with MitraClip™ was achieved with a high technical success rate. It was associated with significant reduction in MR severity and improvement in functional capacity in >90 % of the subjects.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian heart journal CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

52 days

期刊介绍： Indian Heart Journal (IHJ) is the official peer-reviewed open access journal of Cardiological Society of India and accepts articles for publication from across the globe. The journal aims to promote high quality research and serve as a platform for dissemination of scientific information in cardiology with particular focus on South Asia. The journal aims to publish cutting edge research in the field of clinical as well as non-clinical cardiology - including cardiovascular medicine and surgery. Some of the topics covered are Heart Failure, Coronary Artery Disease, Hypertension, Interventional Cardiology, Cardiac Surgery, Valvular Heart Disease, Pulmonary Hypertension and Infective Endocarditis. IHJ open access invites original research articles, research briefs, perspective, case reports, case vignette, cardiovascular images, cardiovascular graphics, research letters, correspondence, reader forum, and interesting photographs, for publication. IHJ open access also publishes theme-based special issues and abstracts of papers presented at the annual conference of the Cardiological Society of India.